Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa
Insights

Security software stocks face a fresh profit test

  • BlackBerry reported Q1 FY2027 revenue of $152.9 million, up 26% year over year, with adjusted EBITDA of $36.3 million and GAAP operating income of $15.3 million.
  • The comparison group shows a wide revenue gap, from Cerence’s $64.2 million quarterly revenue to Palo Alto Networks’ $3 billion quarterly revenue.
  • The main sector test is whether AI security, connected-vehicle software, and government communications can keep growing while margins stay under control.
Read more: Security software stocks face a fresh profit test
Grafa
Insights

Australia’s tax overhaul shifts capital to new builds

  • The federal government has secured the passage of its first budget tax reform tranche by forming a Senate alliance with the Australian Greens.
  • The structural compromise removes a 50% capital gains tax discount, introduces cost base indexation, and applies a 30% minimum capital gains tax from July 1, 2027.
  • A strict ban on self-managed super funds borrowing for residential property shifts structural momentum towards major commercial builders of new housing supply.
Read more: Australia’s tax overhaul shifts capital to new builds
Grafa
Energy

PowerBank wins US federal contract for solar and EV charging project

PowerBank (NASDAQ:PBK) announced that its US subsidiary, Abundant Solar Power, has been awarded a contract by the United States Department of Defense and the Department of the Army to construct a photovoltaic array, electric vehicle chargers, and associated infrastructure at the Armed Forces Reserve Center in Farmingdale, New York.

Read more: PowerBank wins US federal contract for solar and EV charging project
Grafa

Datroway receives positive CHMP opinion for first-line TNBC in EU

Daiichi Sankyo and AstraZeneca (NYSE:AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Datroway (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Read more: Datroway receives positive CHMP opinion for first-line TNBC in EU